Immunotherapy in first-line for advanced non-small cell lung cancer: <br>a cost-effective choice?

Abstract

Combining pharmacological costs of drugs with the measure of efficacy represented by OS, pembrolizumab is a cost-effective first-line treatment for patients with metastatic NSCLC.